22 completed, 8 unknown, 5 recruiting, 4 active not recruiting. 11 Phase 4, 9 Phase 1, 9 Phase 2, 5 Not applicable, 5 Phase 3.
Follow Physiological Effects of Drugs: new trials by email Literature Review of Physiological Effects of Drugs trials Research Report on Physiological Effects of Drugs
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO IV-EPIC 38) Drug-coated balloon, Single antiplatelet therapy (SAPT), Dual antiplatelet therapy (DAPT) - Coronary Disease, Heart Diseases | Not applicable | Recruiting | Fondazione Ricerca e Innovazione Cardiovascolare ETS | 576 | 2026-01-10 | 2026-01-22 |
| A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in Europe (PLATINUM EU) NT 201, NT 201 Placebo - Neuromuscular Agents, Peripheral Nervous System Agents | Phase 3 | Active not recruiting | Merz Aesthetics GmbH | 300 | 2025-10-01 | 2026-09-10 |
| The Study of Efficacy and Safety of Dimephosphon® in Acute Ischemic Stroke Dimephosphon®, Placebo - Stroke, Acute Stroke | Phase 3 | Recruiting | Tatchempharmpreparaty, JSC | 184 | 2025-09-06 | 2025-09-11 |
| A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in the United States NT 201, NT 201 Placebo - Neuromuscular Agents, Peripheral Nervous System Agents | Phase 3 | Active not recruiting | Merz North America, Inc. | 300 | 2025-08-27 | 2026-09-10 |
| Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression (2R,6R)-hydroxynorketamine (0.25 to 2.0 mg/kg), Placebo - Suicide, Depressive Disorder, Treatment-Resistant | Phase 2 | Recruiting | National Institute of Mental Health (NIMH) | 50 | 2024-11-06 | 2026-10-05 |
| Natural History of Depression, Bipolar Disorder and Suicide Risk Behavioral Symptoms, Suicide | Recruiting | National Institute of Mental Health (NIMH) | 500 | 2024-09-09 | 2026-10-01 | |
| Postoperative Urinary Retention After Reversal of Neuromuscular Block by Neostigmine Versus Sugammadex Neostigmine, Sugammadex - Urinary Retention Postoperative, Laparoscopic Cholecystectomy | Phase 4 | Completed | University of Texas Southwestern Medical Center | 235 | 2023-09-11 | 2024-10-09 |
| Screening of Volunteers for Clinical Trials of Investigational or Licensed Vaccines or Antiviral Products Vaccines, Antiviral Agents | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 9 | 2023-04-24 | 2025-05-16 | |
| Effectiveness of the Comfort-In Needle Free Injection System During Palatal Infiltrative Anesthesia Comfort-in Jet Injection Method, Traditional Dental Injection - Physiological Effects of Drugs, Anesthetics | Not applicable | Completed | Necmettin Erbakan University | 50 | 2023-01-01 | 2026-04-30 |
| Oral Aspirin + Ketamine as Adjunct to Oral Antidepressant Therapy for Depression VTS-K - Treatment Resistant Depression, Major Depressive Disorder | Phase 4 | Completed | Theresa Jacob, PhD, MPH | 15 | 2022-12-06 | 2026-04-21 |
| Ad26.ZEBOV, MVA-BN-Filo Vaccination in Children and Adults Previously Vaccinated With Control in the EBOVAC-Salone Study Ad26.ZEBOV, MVA-BN-Filo - Virus Diseases, Hemorrhagic Fever, Ebola | Phase 2 | Completed | London School of Hygiene and Tropical Medicine | 133 | 2022-09-19 | 2025-05-11 |
| Propranolol on Post Stroke Immune Status and Infection Propranolol, Ceftriaxone - Stroke, Cerebrovascular Disorders | Phase 2 | Unknown | Tianjin Medical University General Hospital | 45 | 2022-06-01 | 2022-05-16 |
| A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer) Abemaciclib, Abiraterone, Prednisone or Prednisolone - Prostatic Neoplasms, Neoplasm Metastasis | Phase 3 | Active not recruiting | Eli Lilly and Company | 925 | 2022-04-14 | 2026-07-01 |
| Immunomodulatory Effect of Dexmedetomidine as an Adjuvant Drug in Laparoscopic Cholecystectomies Dexmedetomidine Hydrochloride - Physiological Effects of Drugs | Phase 3 | Unknown | Universidade Federal do Rio de Janeiro | 52 | 2022-04-01 | 2022-08-05 |
| Azithromycin to Improve Latency in Exam Indicated Cerclage Control Trial Azithromycin 1 gram IV, Cefazolin and indomethacin - Preterm Birth, Obstetric Labor, Premature | Phase 4 | Unknown | Thomas Jefferson University | 50 | 2021-12-20 | 2023-06-26 |
| Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder LY03010 156 mg treatment group, deltoid, LY03010 156 mg treatment group, gluteal, LY03010 351 mg treatment group, deltoid - Schizophrenia, Psychotic Disorders | Phase 1 | Completed | Luye Pharma Group Ltd. | 89 | 2021-09-08 | 2024-03-19 |
| The Combination of Sitagliptin and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia Sitagliptin, Danazol - Immune Thrombocytopenia, Blood Coagulation Disorders | Phase 2 | Unknown | Peking University People's Hospital | 120 | 2021-06-01 | 2022-04-29 |
| Comparison Between Natural Sleep Endoscopy and Drug-induced Sleep Endoscopy in Patients With Obstructive Sleep Apnea Drug-induced sleep endoscopy, Natural sleep endoscopy - Sleep Apnea, Obstructive, Sleep Apnea | Not applicable | Unknown | ethisch.comite@uza.be | 40 | 2021-03-30 | 2021-07-26 |
| Relative Bioavailability of LY03010 Compared to Listed Drug LY03010; paliperidone palmitate, INVEGA SUSTENNA - Schizophrenia, Psychotic Disorders | Phase 1 | Completed | Luye Pharma Group Ltd. | 281 | 2021-01-13 | 2023-04-25 |
| Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome Guanfacine Extended Release, Placebo - Prader-Willi Syndrome, Aggression | Phase 4 | Completed | Maimonides Medical Center | 15 | 2020-12-17 | 2024-08-19 |
Showing 20 of 44. Sign in to see all of them.
Mental Disorders (6) · Nervous System Diseases (5) · RNA Virus Infections (5) · Virus Diseases (5) · Behavioral Symptoms (3) · Cardiovascular Diseases (3) · Depression (3) · Depressive Disorder, Major (3) · Depressive Disorder, Treatment-Resistant (3) · Immune System Diseases (3) · Mood Disorders (3) · Neoplasms by Histologic Type (3) · Respiratory Tract Diseases (3) · Respiratory Tract Infections (3) · Schizophrenia (3)
Pathological Conditions, Signs and Symptoms (11) · Behavior (9) · Mental Disorders (7) · Pathologic Processes (6) · Signs and Symptoms (6) · Hemic and Lymphatic Diseases (5) · Nutritional and Metabolic Diseases (5) · Infections (4) · Nervous System Diseases (4) · Neurologic Manifestations (4) · Female Urogenital Diseases (3) · Female Urogenital Diseases and Pregnancy Complications (3) · Genital Diseases (3) · Health Behavior (3) · Hematologic Diseases (3)
Dexmedetomidine (3) · Ethanol (2) · Paliperidone Palmitate (2) · empagliflozin (2) · incobotulinumtoxinA (2) · 6-hydroxynorketamine (1) · Aspirin (1) · Cefazolin (1) · Ceftriaxone (1) · Danazol (1) · Dydrogesterone (1) · Guanfacine (1) · Indomethacin (1) · Ketamine (1) · Memantine (1)
Celularity Incorporated (4) · Luye Pharma Group Ltd. (2) · National Institute of Mental Health (NIMH) (2) · University of California, Los Angeles (2) · University of Chicago (2) · University of Texas Southwestern Medical Center (2) · Ankara City Hospital Bilkent (1) · Butantan Institute (1) · CRG UZ Brussel (1) · Centre for Addiction and Mental Health (1) · Diamyd Medical AB (1) · Eli Lilly and Company (1) · Fondazione Ricerca e Innovazione Cardiovascolare ETS (1) · Janssen Korea, Ltd., Korea (1) · Jiangsu HengRui Medicine Co., Ltd. (1)
United States (21) · Canada (5) · China (5) · Belgium (3) · Brazil (3) · Spain (3) · Czechia (2) · France (2) · Germany (2) · Italy (2) · Netherlands (2) · Poland (2) · South Korea (2) · Turkey (Türkiye) (2) · Argentina (1)
Rui Li, MD (2) · Adrian Kilcoyne, MD (1) · Alexander Precioso, MD, PhD (1) · Carlos A Zarate, M.D. (1) · Corey Casper, MD MPH (1) · Deborah Watson-Jones, PhD (1) · Deepan Singh, MD (1) · Elizabeth D Ballard, Ph.D. (1) · Gustavo Silva, MD (1) · Halenur Altan (1) · Harriet de Wit (1) · Herman Tournaye, PhD, MD (1)
PMID 18582848, PMID 32328115, PMID 32446470, PMID 33201577, PMID 33849856, PMID 34021020, PMID 34184312, PMID 34852779, PMID 34950101, PMID 35665810, PMID 36349701, PMID 36480510, PMID 36817467, PMID 37604516, PMID 40336058, PMID 41135925, PMID 41789933, PMID 42752599
2017 (1), 2018 (1), R01AI114903 (1)